Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
4.008 EUR | -0.05% | -1.57% | -15.08% |
PARIS (Reuters) - Shares in biotech firm Valneva dropped as much as 6.9% on Tuesday after the European Union drug regulator said the firm's COVID-19 vaccine was under an EU rolling review but it was still awaiting some additional data.
Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
1st Jan change | Capi. | |
---|---|---|
-15.08% | 60Cr | |
+64.23% | 6.26TCr | |
-2.31% | 4.12TCr | |
+44.36% | 4.03TCr | |
-8.29% | 2.79TCr | |
+11.97% | 2.62TCr | |
-21.16% | 1.91TCr | |
+7.54% | 1.31TCr | |
+27.17% | 1.21TCr | |
+25.72% | 1.23TCr |